Chr. Hansen posted a 13.2 percent increase in revenue to $325 million compared to the corresponding third quarter of Fiscal 2021.  The Company achieved an organic growth rate of nine percent driven by increased volume.  The principal business segments including Bioprotection, Plant Health and HMO grew by 29 percent with core businesses improving growth by seven percent, contributing to a Group organic growth rate of 11 percent.  Food Cultures and Enzymes increased by six percent, based on higher volume.  Health and Nutrition grew by 13 percent, also influenced by volume. 

Chr. Hansen increased EBIT by 3.6 percent to $87 million, mainly due to strong performance in the Health and Nutrition segment.  The EBIT margin declined by 26.7 percent due to higher input costs attributed to disruption within supply chains and loss of business in Russia, partly offset by improvements in production efficiency.

In commenting on results, CEO Mauricio Graber stated, “The execution of our strategy to differentiate as a focused microbial and fermentation technology company continue to deliver solid results in the third quarter.”

Chr. Hansen amended guidance for Fiscal 2022 predicting a growth of 7 to 11 percent, and EBIT margin ranging from 26 to 27 percent.